Experimental drug to reduce opioid constipation

May 22, 2012 (Honolulu, Hawaii) - an experimental drug, CB-5945, chronic non-cancer pain patients receiving opioid therapy, may reduce constipation is a new Phase 2 trial.
0.10 mg twice daily medications, research participants, a quarter, half by the 0.25 mg two times a day helps.Tells WebMD Medical News, response, drug manufacturers, Lee M.Techner, Cubist Pharmaceuticals, Inc., Massachusetts, USA DPM clinical research vice president at Dun column nemesis - "We see a very nice dose.31. Annual Scientific Meeting, American Pain Society (APS) report the results. Working initially in October 2011, Adolor Corporation has developed a drug buy at Cubist, which was funded by Cubist Pharmaceuticals.Intestinal peristalsisCB-5 formerly known as the ADL5945 945 to compete with opioids in opioid receptor binding, is believed to be responsible for the effect of intestinal peristalsis, Dr. Techner said. At the same time, competition may play a role in the delta opioid receptor, is available, he said.Function in patients with constipation due to opioid but not always laxatives, can cause adverse reactions, said Dr. Techner.Currently, the U.S. Food and Drug Administration only 1 opioid receptor antagonist methylnaltrexone treatment of opioid constipation (Salix Pharmaceuticals, Inc. RELISTOR in,) is approved for.Patients must injection of methylnaltrexone, LC CB paper No. 5945 having an oral dosage form.Randomized 45 patients who received placebo twice a day, 43 to 0.10 mg twice daily of experimental drugs, to test the effectiveness of Dr. Techner and colleagues, to CB 5945.56 0.25 mg twice a day once a day 45-5945 -5945 CB Paper No CB, 41 placebo once a day.Patients receiving 30-1284 mg of morphine equivalent per day with an average of 3.4 years, lived in constipation due to opioids. 57% of the drug for back pain.Fecal spontaneous increase in the ratio of the 0.25 mg, 55.6% of the patients twice a day, 27.9% and 0.10 mg twice a day, twice a day received placebo ranging from 25.6% of the report.Response of the 0.25 mg twice daily, low dose and rate of those taking placebo difference (p = 0.0052) were statistically significant.First placebo, once daily, once daily with 0.25 mg of the drug compared to 42.5% of individuals that said response to 29.3%.Each treatment group, the 1-week average increase in bone marrow following spontaneous number is as follows:2:42 for those receiving placebo once a day2.46, placebo twice a dayLow-dose, twice a day for those receiving 3.11(P = 0.0118) was statistically significant for those who once daily high-dose 3:39.(P = 0.0003) was significantly higher doses twice a day to 4.62 victims.High placebo responseThese figures, Edward Michna, MD, JD, Brigham and working anesthetist did not take place in Cambridge, Massachusetts, does not affect Women's Hospital."This is a very high placebo response," he tells WebMD Medical News. However, a similar study in accounting 34.2% for patients who responded to methylnaltrexone 9.9%, placebo inMay Journal of Pain, Dr. Michna and colleagues published in 2011.Dr. Michna Brigham and Women's Hospital, said doctors had found no use for methylnaltrexone, he objected to only a small minority believes that the new drugs."For me this is very difficult to find patients who need these drugs," he said. "We often no problem. It is rare in our prescription constipation, chronic opioid has more than 1,000 cases, or may be a laxative."To stop this opioid side effects of opioids to treat patients with constipation before it becomes necessary for the claim that experience.However, he believes that the advantages of patient types may want to join the CB-5, which will for the first time opioids in acute injuries, including opioids and 945 patients with chronic diseases such as osteoarthritis, or who is to take patients' perioperative opioids.Even so, the market will be limited to the cost of new drugs. If there is no improvement in his heart of their cheaper drugs, the patient usually can not get insurance coverage methylnaltrexone, he said.It can reduce side effects, because the input force gradually, because in addition to, oral agents, methylnaltrexone to address more than patients, it is recommended that Techner Dr. CB-5945.CB-5945, research and treatment-related side effects, rate of 0.25 mg twice a day, 0.25 mg once daily group ranges from 4% to 15% and 15% of patients experience placebo once a day. Compared with placebo, the Police, concluded that: "Dr. Techner.Dr. Michna, you can enjoy a different time of onset. "For some patients, perhaps slower than better," he said. "Other patients may prefer to have an immediate effect."Drug to enter Phase III trials, Dr. Techner say.This research is funded by Cubist Pharmaceuticals. Dr Techna that Cubist Pharmaceuticals, CB-5. 1000 2.9 45 reveal that the manufacturer's employees, and as a consultant, Dr. Michna that Salix, where it serves as a manufacturer of methylnaltrexone emerges.American Pain Society (APS) 31 th Annual Scientific Meeting.Abstract # 434, May 17, 2012.,